Certara (NASDAQ:CERT) Hits New 52-Week Low – Here’s What Happened

Certara, Inc. (NASDAQ:CERT) shares hit a new 52-week low on Monday . The company traded as low as $5.63 and last traded at $5.6240, with a volume of 4361473 shares trading hands. The stock had previously closed at $5.75.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on CERT shares. Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a report on Monday, December 29th. Leerink Partners reissued an “outperform” rating and issued a $10.00 target price on shares of Certara in a research report on Thursday, February 26th. Wall Street Zen cut Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Morgan Stanley lowered their price target on Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Finally, Barclays reiterated an “equal weight” rating and issued a $8.00 price objective on shares of Certara in a report on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $11.10.

Certara Stock Performance

The stock has a market capitalization of $903.92 million, a PE ratio of -568.00 and a beta of 1.50. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05. The firm’s 50 day moving average is $7.35 and its two-hundred day moving average is $9.29.

Certara (NASDAQ:CERT) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the business earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, research analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Tejara Capital Ltd increased its stake in shares of Certara by 94.9% during the third quarter. Tejara Capital Ltd now owns 273,052 shares of the company’s stock worth $3,337,000 after buying an additional 132,927 shares during the period. Sector Gamma AS purchased a new position in Certara in the third quarter worth approximately $2,818,000. Kopion Asset Management LLC grew its holdings in Certara by 49.9% during the 4th quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after acquiring an additional 327,064 shares in the last quarter. Fort Washington Investment Advisors Inc. OH acquired a new position in Certara during the 3rd quarter worth approximately $11,899,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Certara in the 2nd quarter valued at approximately $329,000. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.